Trial Profile
Novel Therapy Combining Regenerative Stimuli Immunomodulation to Preserve Beta Cell Function in New Onset Type 1 Diabetes.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs GAD65 vaccine (Diamyd) (Primary) ; Lansoprazole (Primary) ; Sitagliptin (Primary) ; Insulin
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 20 Mar 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 30 Mar 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
- 30 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.